January | 2026
Acandis’ market entry in Canada represents a major milestone in expanding global patient access
Acandis continues its international expansion and is now officially present on the Canadian market with its portfolio. The first applications with DERIVO® 2heal® embolisation device have already been successfully performed and have demonstrated excellent device opening, smooth delivery, and best-in-class visualisation.
The Acandis’ market entry in Canada strengthens the company’s global presence in neurovascular care and further establishes its role as an innovation partner for clinics and specialists.
It is an important step towards providing patients worldwide with access to advanced treatment options for neurovascular diseases. Acandis is committed to its strategy of integrating pioneering technologies into an ever-growing number of healthcare systems, thereby improving care quality sustainably.
Read more on LinkedIn